Last updated: February 24, 2026
What is NDC 42571-0360?
NDC 42571-0360 refers to a specific drug product listed in the U.S. National Drug Code directory. This code typically identifies a branded or generic pharmaceutical formulation, including medication name, dosage form, strength, and manufacturer.
Based on available data, NDC 42571-0360 is associated with Vosevi (sofosbuvir, velpatasvir, and voxilaprevir), used for treatment of chronic hepatitis C virus (HCV) infection.
Market Overview
Therapeutic Area
- Indication: Chronic hepatitis C
- Treatment landscape:
- Highly competitive segment
- Major players: Gilead Sciences, AbbVie, Merck, and others
- Growing adoption driven by new guidelines recommending direct-acting antivirals (DAAs)
Market Size (2022 Data)
| Metric |
Value |
Source |
| U.S. HCV prevalence |
2.4 million |
CDC[1] |
| Annual treatment market |
$2.3 billion (approximate) |
IQVIA[2] |
| Market growth rate (2020-2025) |
8% CAGR |
EvaluatePharma[3] |
Competitive Position
- Vosevi entered the market in 2017 as a highly effective combination for retreating HCV, including cases resistant to prior therapies.
- Offers a shorter treatment duration (12 weeks) compared to earlier regimens.
- Competitors include Mavyret (glecaprevir/pibrentasvir) and Epclusa (sofosbuvir/velpatasvir).
Price Trends and Projections
Current Pricing
- List price per 28-day supply: Approx. $24,000
- Average net price (after discounts, rebates): $16,000 - $18,000
Pricing Dynamics
- The list price has remained relatively stable since FDA approval.
- Manufacturer discounts and rebates, paid by pharmacies and insurers, significantly impact net prices.
- Medicare and Medicaid programs negotiate substantial discounts, reducing payer costs.
Price Projections (Next 3-5 Years)
- Assumption: Continued competition, patent protections extending into the late 2020s.
- Expected trend: Slight downward pressure on prices due to biosimilar and generic entrants for components like sofosbuvir.
- Predicted decrease in net prices by 10-15% over five years, driven by increased competition and volume-based discounts.
Regulatory and Policy Impact
- FDA approvals of generics or biosimilars could lead to additional price reductions.
- Payer cost-containment measures may further influence net prices.
Market Entry and Growth Barriers
- High development costs for competitors (~$1.5 billion for new DAAs).
- Patent exclusivity till 2028-2030, limiting immediate generics.
- Patent challenges or litigation can delay pricing erosion.
Investment and R&D Implications
- R&D focus shifts towards pan-genotypic treatments and shorter durations.
- Innovator companies may modify formulations, license existing patents, or develop combination therapies to sustain market position.
Key Takeaways
- NDC 42571-0360 (Vosevi) holds a significant position within the HCV treatment segment.
- Market size is stable, with a moderate growth trajectory driven by global expansion.
- The current price per treatment cycle remains around $24,000, with substantial discounts reducing payer costs.
- Long-term price reductions are anticipated due to patent expiration, increased biosimilar activity, and regulatory pressures.
- Companies should monitor patent litigation, regulatory approvals, and market share shifts to inform investment and R&D strategies.
FAQs
1. What are the main competitors for NDC 42571-0360?
Mavyret (glecaprevir/pibrentasvir) and Epclusa (sofosbuvir/velpatasvir) are primary competitors, offering similar efficacy with different dosing regimens.
2. How stable are the current drug prices?
Current list prices have remained stable since launch, but net prices are declining due to discounts, rebates, and negotiations.
3. When will biosimilars or generics affect the market?
Potential patent expirations around 2028-2030 open the market to biosimilar competition, likely reducing prices.
4. How does treatment adherence impact market size?
Simpler regimens (12-week courses, fewer pills) improve adherence, expanding market penetration.
5. What regulatory factors could influence prices?
FDA approvals of generics, biosimilars, and policy measures aimed at drug price reductions are key considerations.
References
[1] Centers for Disease Control and Prevention. (2022). Hepatitis C FAQs for Health Professionals.
[2] IQVIA. (2022). The Global Use of Medicines: Outlook From 2022 to 2026.
[3] EvaluatePharma. (2022). World Preview: The Top 20 Brands by Sales.
Please advise if you require detailed patent status, specific market share figures, or regulatory timelines.
